Polielektrolit-frakcionált porcin VIII. faktor egy esetben való alkalmazásáról gátlótestes haemophiliában.

Translated title of the contribution: Poly-electrolyte fractionated porcine factor VIII in the treatment of hemophilia A

T. Ferencz, J. Skopál, C. Csáki, M. Laczkó, D. Schuler, J. Borsi

Research output: Contribution to journalArticle

Abstract

In approximately 10 to 15 percent of congenital hemophilia A patients circulating antibodies to factor VIII appear in the blood that poses a serious problem in their treatment. A number of methods and preparations are used in the clinical practice to overcome this problem. Authors report their favourable clinical experience with the administration of polyelectrolyte-fractionated porcine factor VIII. concentrate in a hemophiliac child for the first time in Hungary and a brief review of the clinical methods in use in the management of factor VIII. inhibitors.

Original languageHungarian
Pages (from-to)2873-2875
Number of pages3
JournalOrvosi Hetilap
Volume134
Issue number52
Publication statusPublished - Dec 26 1993

Fingerprint

Factor VIII
Hemophilia A
Electrolytes
Swine
Hungary
Therapeutics
Antibodies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ferencz, T., Skopál, J., Csáki, C., Laczkó, M., Schuler, D., & Borsi, J. (1993). Polielektrolit-frakcionált porcin VIII. faktor egy esetben való alkalmazásáról gátlótestes haemophiliában. Orvosi Hetilap, 134(52), 2873-2875.

Polielektrolit-frakcionált porcin VIII. faktor egy esetben való alkalmazásáról gátlótestes haemophiliában. / Ferencz, T.; Skopál, J.; Csáki, C.; Laczkó, M.; Schuler, D.; Borsi, J.

In: Orvosi Hetilap, Vol. 134, No. 52, 26.12.1993, p. 2873-2875.

Research output: Contribution to journalArticle

Ferencz, T, Skopál, J, Csáki, C, Laczkó, M, Schuler, D & Borsi, J 1993, 'Polielektrolit-frakcionált porcin VIII. faktor egy esetben való alkalmazásáról gátlótestes haemophiliában.', Orvosi Hetilap, vol. 134, no. 52, pp. 2873-2875.
Ferencz, T. ; Skopál, J. ; Csáki, C. ; Laczkó, M. ; Schuler, D. ; Borsi, J. / Polielektrolit-frakcionált porcin VIII. faktor egy esetben való alkalmazásáról gátlótestes haemophiliában. In: Orvosi Hetilap. 1993 ; Vol. 134, No. 52. pp. 2873-2875.
@article{cb1d2ea45f9d46a9ada4e02e5aef79b4,
title = "Polielektrolit-frakcion{\'a}lt porcin VIII. faktor egy esetben val{\'o} alkalmaz{\'a}s{\'a}r{\'o}l g{\'a}tl{\'o}testes haemophili{\'a}ban.",
abstract = "In approximately 10 to 15 percent of congenital hemophilia A patients circulating antibodies to factor VIII appear in the blood that poses a serious problem in their treatment. A number of methods and preparations are used in the clinical practice to overcome this problem. Authors report their favourable clinical experience with the administration of polyelectrolyte-fractionated porcine factor VIII. concentrate in a hemophiliac child for the first time in Hungary and a brief review of the clinical methods in use in the management of factor VIII. inhibitors.",
author = "T. Ferencz and J. Skop{\'a}l and C. Cs{\'a}ki and M. Laczk{\'o} and D. Schuler and J. Borsi",
year = "1993",
month = "12",
day = "26",
language = "Hungarian",
volume = "134",
pages = "2873--2875",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "52",

}

TY - JOUR

T1 - Polielektrolit-frakcionált porcin VIII. faktor egy esetben való alkalmazásáról gátlótestes haemophiliában.

AU - Ferencz, T.

AU - Skopál, J.

AU - Csáki, C.

AU - Laczkó, M.

AU - Schuler, D.

AU - Borsi, J.

PY - 1993/12/26

Y1 - 1993/12/26

N2 - In approximately 10 to 15 percent of congenital hemophilia A patients circulating antibodies to factor VIII appear in the blood that poses a serious problem in their treatment. A number of methods and preparations are used in the clinical practice to overcome this problem. Authors report their favourable clinical experience with the administration of polyelectrolyte-fractionated porcine factor VIII. concentrate in a hemophiliac child for the first time in Hungary and a brief review of the clinical methods in use in the management of factor VIII. inhibitors.

AB - In approximately 10 to 15 percent of congenital hemophilia A patients circulating antibodies to factor VIII appear in the blood that poses a serious problem in their treatment. A number of methods and preparations are used in the clinical practice to overcome this problem. Authors report their favourable clinical experience with the administration of polyelectrolyte-fractionated porcine factor VIII. concentrate in a hemophiliac child for the first time in Hungary and a brief review of the clinical methods in use in the management of factor VIII. inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=0027924613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027924613&partnerID=8YFLogxK

M3 - Article

VL - 134

SP - 2873

EP - 2875

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 52

ER -